28 results on '"Karampatou, A"'
Search Results
2. Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis
- Author
-
Villa, Erica, Cammà, Calogero, Marietta, Marco, Luongo, Monica, Critelli, Rosina, Colopi, Stefano, Tata, Cristina, Zecchini, Ramona, Gitto, Stefano, Petta, Salvatore, Lei, Barbara, Bernabucci, Veronica, Vukotic, Ranka, De Maria, Nicola, Schepis, Filippo, Karampatou, Aimilia, Caporali, Cristian, Simoni, Luisa, Del Buono, Mariagrazia, Zambotto, Beatrice, Turola, Elena, Fornaciari, Giovanni, Schianchi, Susanna, Ferrari, Anna, and Valla, Dominique
- Published
- 2012
- Full Text
- View/download PDF
3. Pharmacotherapy of Painful Diabetic Neuropathy: A Clinical Update
- Author
-
Cornelius Fernandez, James, Shiva, Tripathi, Kyriaki, Karampatou, Divya V, Gladston, and Joseph M, Pappachan
- Abstract
The rising prevalence of diabetes mellitus (DM) leads on to an increase in chronic diabetic complications. Diabetic peripheral neuropathies (DPNs) are common chronic complications of diabetes. Distal symmetric polyneuropathy is the most prevalent form. Most patients with DPN will remain pain-free; however, painful DPN (PDPN) occurs in 6-34% of all DM patients and is associated with reduced health-related-quality-of-life and substantial economic burden. Symptomatic treatment of PDPN and diabetic autonomic neuropathy is the key treatment goals. Using certain patient related characteristics, subjects with PDPN can be stratified and assigned targeted therapies to produce better pain outcomes. The aim of this review is to discuss the various pathogenetic mechanisms of DPN with special reference to the mechanisms leading to PDPN and the various pharmacological and non-pharmacological therapies available for its management. Recommended pharmacological therapies include anticonvulsants, antidepressants, opioid analgesics, and topical medications.
- Published
- 2021
4. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)
- Author
-
Karampatou A., Karampatou, A, Han, X, Kondili, L, Taliani, G, Ciancio, A, Morisco, F, Critelli, R, Baraldi, E, Bernabucci, V, Troshina, G, Guarino, M, Tagliavini, S, D'Ambrosio, F, Bristot, L, Turco, L, Rosato, S, Vella, S, Trenti, T, Neri, I, La Marca, A, Manthena, S, Goldstein, A, Bruno, S, Bao, Y, Gonzalez, Y, Villa, E, Craxi, A, Petta, S, Calvaruso, V, Brunetto, M, Coco, B, Chessa, L, Pasetto, M, Bigliotti, E, Tamburrini, F, Montalto, G, Capitano, A, Ieluzzi, D, Fattovich, G, Zignego, A, Monti, M, Gragnani, L, Zuin, M, Finati, E, Giorgini, A, Angarano, G, Milella, M, Alessandro, F, Dallio, M, Mazzella, G, Lazzarini, G, Di Fine, M, Russo, F, Zanetto, A, Castelli, F, Zaltron, S, Raimondo, G, Filomia, R, Puoti, M, Danieli, E, Strazzabosco, M, Gemma, M, Angelico, M, De Leonardis, F, Gori, A, Cappelletti, E, Bruno, R, Cima, S, Coppola, C, Amoruso, D, Andreone, P, Simonetti, G, Gaeta, G, Brancaccio, G, Toniutto, P, Dissegna, D, Mondelli, M, Ludovisi, S, Persico, M, Masarone, M, Torti, C, Strazzulla, A, Rosina, F, Framarin, L, Weimer, L, Quaranta, M, Falzano, L, Mallano, A, Karampatou A., Han X., Kondili L. A., Taliani G., Ciancio A., Morisco F., Critelli R. M., Baraldi E., Bernabucci V., Troshina G., Guarino M., Tagliavini S., D'Ambrosio F., Bristot L., Turco L., Rosato S., Vella S., Trenti T., Neri I., La Marca A., Manthena S., Goldstein A. S., Bruno S., Bao Y., Gonzalez Y. S., Villa E., Craxi A., Petta S., Calvaruso V., Brunetto M., Coco B., Chessa L., Pasetto M. C., Bigliotti E., Tamburrini F., Montalto G., Capitano A. R., Ieluzzi D., Fattovich G., Zignego A. L., Monti M., Gragnani L., Zuin M., Finati E., Giorgini A., Angarano G., Milella M., Alessandro F., Dallio M., Mazzella G., Lazzarini G., Di Fine M., Russo F. P., Zanetto A., Castelli F., Zaltron S., Raimondo G., Filomia R., Puoti M., Danieli E., Strazzabosco M., Gemma M., Angelico M., De Leonardis F., Gori A., Cappelletti E., Bruno R., Cima S., Coppola C., Amoruso D. C., Andreone P., Simonetti G., Gaeta G. B., Brancaccio G., Toniutto P., Dissegna D., Mondelli M., Ludovisi S., Persico M., Masarone M., Torti C., Strazzulla A., Rosina F., Framarin L., Weimer L. E., Quaranta M. G., Falzano L., Mallano A., Karampatou A., Karampatou, A, Han, X, Kondili, L, Taliani, G, Ciancio, A, Morisco, F, Critelli, R, Baraldi, E, Bernabucci, V, Troshina, G, Guarino, M, Tagliavini, S, D'Ambrosio, F, Bristot, L, Turco, L, Rosato, S, Vella, S, Trenti, T, Neri, I, La Marca, A, Manthena, S, Goldstein, A, Bruno, S, Bao, Y, Gonzalez, Y, Villa, E, Craxi, A, Petta, S, Calvaruso, V, Brunetto, M, Coco, B, Chessa, L, Pasetto, M, Bigliotti, E, Tamburrini, F, Montalto, G, Capitano, A, Ieluzzi, D, Fattovich, G, Zignego, A, Monti, M, Gragnani, L, Zuin, M, Finati, E, Giorgini, A, Angarano, G, Milella, M, Alessandro, F, Dallio, M, Mazzella, G, Lazzarini, G, Di Fine, M, Russo, F, Zanetto, A, Castelli, F, Zaltron, S, Raimondo, G, Filomia, R, Puoti, M, Danieli, E, Strazzabosco, M, Gemma, M, Angelico, M, De Leonardis, F, Gori, A, Cappelletti, E, Bruno, R, Cima, S, Coppola, C, Amoruso, D, Andreone, P, Simonetti, G, Gaeta, G, Brancaccio, G, Toniutto, P, Dissegna, D, Mondelli, M, Ludovisi, S, Persico, M, Masarone, M, Torti, C, Strazzulla, A, Rosina, F, Framarin, L, Weimer, L, Quaranta, M, Falzano, L, Mallano, A, Karampatou A., Han X., Kondili L. A., Taliani G., Ciancio A., Morisco F., Critelli R. M., Baraldi E., Bernabucci V., Troshina G., Guarino M., Tagliavini S., D'Ambrosio F., Bristot L., Turco L., Rosato S., Vella S., Trenti T., Neri I., La Marca A., Manthena S., Goldstein A. S., Bruno S., Bao Y., Gonzalez Y. S., Villa E., Craxi A., Petta S., Calvaruso V., Brunetto M., Coco B., Chessa L., Pasetto M. C., Bigliotti E., Tamburrini F., Montalto G., Capitano A. R., Ieluzzi D., Fattovich G., Zignego A. L., Monti M., Gragnani L., Zuin M., Finati E., Giorgini A., Angarano G., Milella M., Alessandro F., Dallio M., Mazzella G., Lazzarini G., Di Fine M., Russo F. P., Zanetto A., Castelli F., Zaltron S., Raimondo G., Filomia R., Puoti M., Danieli E., Strazzabosco M., Gemma M., Angelico M., De Leonardis F., Gori A., Cappelletti E., Bruno R., Cima S., Coppola C., Amoruso D. C., Andreone P., Simonetti G., Gaeta G. B., Brancaccio G., Toniutto P., Dissegna D., Mondelli M., Ludovisi S., Persico M., Masarone M., Torti C., Strazzulla A., Rosina F., Framarin L., Weimer L. E., Quaranta M. G., Falzano L., and Mallano A.
- Abstract
It has come to our attention that the PITER framework investigator, Alessandro Federico, was incorrectly listed as F. Alessandro in the original manuscript. Please note that the correct name of this author is Alessandro Federico (2nd University of Naples). The correct list of PITER investigators is in the footnote below.
- Published
- 2018
5. Reproductive status is associated with the severity of fibrosis in women with hepatitis C.
- Author
-
Erica Villa, Ranka Vukotic, Calogero Cammà, Salvatore Petta, Alfredo Di Leo, Stefano Gitto, Elena Turola, Aimilia Karampatou, Luisa Losi, Veronica Bernabucci, Annamaria Cenci, Simonetta Tagliavini, Enrica Baraldi, Nicola De Maria, Roberta Gelmini, Elena Bertolini, Maria Rendina, and Antonio Francavilla
- Subjects
Medicine ,Science - Abstract
Chronic hepatitis C is the main cause of death in patients with end-stage liver disease. Prognosis depends on the increase of fibrosis, whose progression is twice as rapid in men as in women. Aim of the study was to evaluate the effects of reproductive stage on fibrosis severity in women and to compare these findings with age-matched men.A retrospective study of 710 consecutive patients with biopsy-proven chronic hepatitis C was conducted, using data from a clinical database of two tertiary Italian care centers. Four age-matched groups of men served as controls. Data about demographics, biochemistry, liver biopsy and ultrasonography were analyzed. Contributing factors were assessed by multivariate logistic regression analysis.Liver fibrosis was more advanced in the early menopausal than in the fully reproductive (P
- Published
- 2012
- Full Text
- View/download PDF
6. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV
- Author
-
Karampatou, Aimilia, Han, Xue, Kondili, Loreta A., Taliani, Gloria, Ciancio, Alessia, Morisco, Filomena, Critelli, Rosina Maria, Baraldi, Enrica, Bernabucci, Veronica, Troshina, Giulia, Guarino, Maria, Tagliavini, Simonetta, D'Ambrosio, Federica, Bristot, Laura, Turco, Laura, Rosato, Stefano, Vella, Stefano, Trenti, Tommaso, Neri, Isabella, La Marca, Antonio, Manthena, Shivaji, Goldstein, Andrea S., Bruno, Savino, Bao, Yanjun, Gonzalez, Yuri Sanchez, Villa, Erica, Craxì, A., Petta, S., Calvaruso, V., Brunetto, M., Coco, B., Chessa, L., Pasetto, M. C., Bigliotti, E., Tamburrini, F., Montalto, G., Capitano, A. R., Ieluzzi, D., Fattovich, G., Zignego, A. L., Monti, M., Gragnani, L., Zuin, M., Finati, E., Giorgini, A., Angarano, G., Milella, M., Federico, A., Alessandro, F., Dallio, M., Mazzella, G., Lazzarini, G., Di Fine, M., Russo, F. P., Zanetto, A., Castelli, F., Zaltron, S., Raimondo, G., Filomia, R., Puoti, M., Danieli, E., Strazzabosco, M., Gemma, M., Angelico, M., De Leonardis, F., Gori, A., Cappelletti, E., Bruno, R., Cima, S., Coppola, C., Amoruso, D. C., Andreone, P., Simonetti, G., Gaeta, G. B., Brancaccio, G., Toniutto, P., Dissegna, D., Mondelli, M., Ludovisi, S., Persico, M., Masarone, M., Torti, C., Strazzulla, A., Rosina, F., Framarin, L., Weimer, L. E., Quaranta, M. G., Falzano, L., Mallano, A., Karampatou, A., Han, X., Kondili, L., Taliani, G., Ciancio, A., Morisco, F., Critelli, R., Baraldi, E., Bernabucci, V., Troshina, G., Guarino, M., Tagliavini, S., D'Ambrosio, F., Bristot, L., Turco, L., Rosato, S., Vella, S., Trenti, T., Neri, I., La Marca, A., Manthena, S., Goldstein, A., Bruno, S., Bao, Y., Gonzalez, Y., Villa, E., Craxi, A., Petta, S., Calvaruso, V., Karampatou, A, Han, X, Kondili, L, Taliani, G, Ciancio, A, Morisco, F, Critelli, R, Baraldi, E, Bernabucci, V, Troshina, G, Guarino, M, Tagliavini, S, D'Ambrosio, F, Bristot, L, Turco, L, Rosato, S, Vella, S, Trenti, T, Neri, I, La Marca, A, Manthena, S, Goldstein, A, Bruno, S, Bao, Y, Gonzalez, Y, Villa, E, Craxi, A, Petta, S, Calvaruso, V, Brunetto, M, Coco, B, Chessa, L, Pasetto, M, Bigliotti, E, Tamburrini, F, Montalto, G, Capitano, A, Ieluzzi, D, Fattovich, G, Zignego, A, Monti, M, Gragnani, L, Zuin, M, Finati, E, Giorgini, A, Angarano, G, Milella, M, Alessandro, F, Dallio, M, Mazzella, G, Lazzarini, G, Di Fine, M, Russo, F, Zanetto, A, Castelli, F, Zaltron, S, Raimondo, G, Filomia, R, Puoti, M, Danieli, E, Strazzabosco, M, Gemma, M, Angelico, M, De Leonardis, F, Gori, A, Cappelletti, E, Bruno, R, Cima, S, Coppola, C, Amoruso, D, Andreone, P, Simonetti, G, Gaeta, G, Brancaccio, G, Toniutto, P, Dissegna, D, Mondelli, M, Ludovisi, S, Persico, M, Masarone, M, Torti, C, Strazzulla, A, Rosina, F, Framarin, L, Weimer, L, Quaranta, M, Falzano, L, Mallano, A, Karampatou, Aimilia, Han, Xue, Kondili, Loreta A., Taliani, Gloria, Ciancio, Alessia, Morisco, Filomena, Critelli, Rosina Maria, Baraldi, Enrica, Bernabucci, Veronica, Troshina, Giulia, Guarino, Maria, Tagliavini, Simonetta, D'Ambrosio, Federica, Bristot, Laura, Turco, Laura, Rosato, Stefano, Vella, Stefano, Trenti, Tommaso, Neri, Isabella, La Marca, Antonio, Manthena, Shivaji, Goldstein, Andrea S., Bruno, Savino, Bao, Yanjun, Gonzalez, Yuri Sanchez, Villa, Erica, Craxì, A., Brunetto, M., Coco, B., Chessa, L., Pasetto, M. C., Bigliotti, E., Tamburrini, F., Montalto, G., Capitano, A. R., Ieluzzi, D., Fattovich, G., Zignego, A. L., Monti, M., Gragnani, L., Zuin, M., Finati, E., Giorgini, A., Angarano, G., Milella, M., Alessandro, F., Dallio, M., Mazzella, G., Lazzarini, G., Di Fine, M., Russo, F. P., Zanetto, A., Castelli, F., Zaltron, S., Raimondo, G., Filomia, R., Puoti, M., Danieli, E., Strazzabosco, M., Gemma, M., Angelico, M., De Leonardis, F., Gori, A., Cappelletti, E., Bruno, R., Cima, S., Coppola, C., Amoruso, D. C., Andreone, P., Simonetti, G., Gaeta, G. B., Brancaccio, G., Toniutto, P., Dissegna, D., Mondelli, M., Ludovisi, S., Persico, M., Masarone, M., Torti, C., Strazzulla, A., Rosina, F., Framarin, L., Weimer, L. E., Quaranta, M. G., Falzano, L., Mallano, A., Pasetto, M.C., Capitano, A.R., Zignego, A.L., Russo, F.P., Amoruso, D.C., Gaeta, G.B., Weimer, L.E., Quaranta, M.G., Craxã¬, A., and Federico, A.
- Subjects
Anti-Mullerian hormone ,Antiviral therapy ,HBV ,HCV ,Sustained viral response ,Hepatology ,Infertility ,medicine.medical_specialty ,media_common.quotation_subject ,Fertility ,Anti-Müllerian hormone ,Miscarriage ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Prospective cohort study ,media_common ,Gynecology ,Anti-Müllerian hormone, Antiviral therapy, HBV, HCV, Sustained viral response ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics ,medicine.disease ,Anti-Müllerian hormone ,Gestational diabetes ,Cohort ,030211 gastroenterology & hepatology ,business ,Live birth ,Cell aging - Abstract
Background & Aims Premenopausal women who are HCV positive (HCV+) have failing ovarian function, which is likely to impact their fertility. Thus, we investigated the reproductive history, risk of infertility, and pregnancy outcomes in women of childbearing age who were HCV+. Methods Three different groups were studied: (1) Clinical cohort: 100 women who were HCV+ and also had chronic liver disease (CLD), age matched with 50 women who were HBV+ with CLD and with 100 healthy women; all women were consecutively observed in three gastroenterology units in hospitals in Italy; (2) 1,998 women who were HCV+ and enrolled in the Italian Platform for the Study of Viral Hepatitis Therapies (PITER); (3) 6,085 women, who were mono-infected with HCV, and 20,415 women, who were HCVâ, from a large de-identified insurance database from the USA. Measurements: total fertility rate (TFR) defined as the average number of children that a woman would bear during her lifetime. To define the reproductive stage of each participant, levels of anti-Müllerian hormone (AMH) and 17β-estradiol were measured. Results Clinical cohort: women who were either HCV+ or HBV+ had similar CLD severity and age at first pregnancy. Based on a multivariate analysis, women who were HCV+ had a higher risk of miscarriage than those who were HBV+ (odds ratio [OR] 6,905; 95% CI 1.771â26.926). Among women who were HCV+, incidence of miscarriage was correlated with median AMH level (1.0 ng/ml). Achieving a sustained virologic response (SVR) after antiviral treatment reduced the risk of miscarriage (OR 0.255; 95% CI 0.090â0.723). In the PITER-HCV cohort, miscarriage occurred in 42.0% of women (44.6% had multiple miscarriages). TFR for women who were HCV+ and between 15 and 49 years of age was 0.7 vs. 1.37 of Italian population of the same age range. In the US cohort: compared with women who were HCVâ, women who were HCV+ positive were significantly more likely to have infertility (OR 2.439; 95% CI 2.130â2.794), premature birth (OR 1.34; 95% CI 1.060â1.690), gestational diabetes (OR 1.24; 95% CI 1.020â1.510), and pre-eclampsia (OR 1.206; 95% CI 0.935â1.556), and were less likely to have a live birth (OR 0.754; 95% CI 0.622â0.913). Conclusions Ovarian senescence in women of childbearing age who are HCV+ is associated with a lower chance of live birth, greater risk of infertility, gestational diabetes, pre-eclampsia and miscarriage. Such risks could be positively influenced by successful HCV cure. Lay summary Most new cases of HCV infection are among people who inject drugs, many of whom are young women in their childbearing years. Women of reproductive age who are HCV+ display markers of ovarian senescence. This is associated with an increased burden in terms of infertility and adverse pregnancy outcomes, including stillbirth, miscarriage, fewer live births, and gestational diabetes. Early viral suppression with therapy is likely to mitigate these risks.
- Published
- 2017
7. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C
- Author
-
Villa, E., Cammà, C., Di Leo, A., Karampatou, A., Enea, M., Gitto, S., Bernabucci, V., Losi, L., De Maria, N., Lei, B., Ferrari, A., Vukotic, R., Vignoli, P., Rendina, M., and Francavilla, A.
- Published
- 2012
- Full Text
- View/download PDF
8. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33-41]
- Author
-
Alessia Ciancio, Aimilia Karampatou, Tommaso Trenti, Veronica Bernabucci, Isabella Neri, Maria Guarino, Stefano Rosato, Laura Bristot, Filomena Morisco, Shivaji Manthena, Laura Turco, Simonetta Tagliavini, Gloria Taliani, Rosina Maria Critelli, Stefano Vella, Federica D'Ambrosio, Antonio La Marca, Savino Bruno, Andrea S. Goldstein, X. Han, Yanjun Bao, Giulia Troshina, Erica Villa, Yuri Sanchez Gonzalez, Enrica Baraldi, Loreta A. Kondili, Karampatou, Aimilia, Han, Xue, Kondili, Loreta A., Taliani, Gloria, Ciancio, Alessia, Morisco, Filomena, Critelli, Rosina Maria, Baraldi, Enrica, Bernabucci, Veronica, Troshina, Giulia, Guarino, Maria, Tagliavini, Simonetta, D'Ambrosio, Federica, Bristot, Laura, Turco, Laura, Rosato, Stefano, Vella, Stefano, Trenti, Tommaso, Neri, Isabella, La Marca, Antonio, Manthena, Shivaji, Goldstein, Andrea S., Bruno, Savino, Bao, Yanjun, Gonzalez, Yuri Sanchez, and Villa, Erica
- Subjects
Gynecology ,Senescence ,medicine.medical_specialty ,Mother to child transmission ,Tenofovir ,Hepatology ,business.industry ,media_common.quotation_subject ,Hbv reactivation ,Fertility ,Hepatitis B ,medicine.disease ,Miscarriage ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,030212 general & internal medicine ,business ,030217 neurology & neurosurgery ,medicine.drug ,media_common - Published
- 2018
9. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)
- Author
-
Karampatou, A., Han, X., Kondili, L. A., Taliani, G., Ciancio, A., Morisco, F., Critelli, R. M., Baraldi, E., Bernabucci, V., Troshina, G., Guarino, M., Tagliavini, S., D'Ambrosio, F., Bristot, L., Turco, L., Rosato, S., Vella, S., Trenti, T., Neri, I., La Marca, A., Manthena, S., Goldstein, A. S., Bruno, S., Bao, Y., Gonzalez, Y. S., Villa, E., Craxi, A., Petta, S., Calvaruso, V., Brunetto, M., Coco, B., Chessa, L., Pasetto, M. C., Bigliotti, E., Tamburrini, F., Montalto, G., Capitano, A. R., Ieluzzi, D., Fattovich, G., Zignego, A. L., Monti, M., Gragnani, L., Zuin, M., Finati, E., Giorgini, A., Angarano, G., Milella, M., Alessandro, F., Dallio, M., Mazzella, G., Lazzarini, G., Di Fine, M., Russo, F. P., Zanetto, A., Castelli, F., Zaltron, S., Raimondo, G., Filomia, R., Puoti, M., Danieli, E., Strazzabosco, M., Gemma, M., Angelico, M., De Leonardis, F., Gori, A., Cappelletti, E., Bruno, R., Cima, S., Coppola, C., Amoruso, D. C., Andreone, P., Simonetti, G., Gaeta, G. B., Brancaccio, G., Toniutto, P., Dissegna, D., Mondelli, M., Ludovisi, S., Persico, M., Masarone, M., Torti, C., Strazzulla, A., Rosina, F., Framarin, L., Weimer, L. E., Quaranta, M. G., Falzano, L., Mallano, A., Karampatou A., Han X., Kondili L.A., Taliani G., Ciancio A., Morisco F., Critelli R.M., Baraldi E., Bernabucci V., Troshina G., Guarino M., Tagliavini S., D'Ambrosio F., Bristot L., Turco L., Rosato S., Vella S., Trenti T., Neri I., La Marca A., Manthena S., Goldstein A.S., Bruno S., Bao Y., Gonzalez Y.S., Villa E., Craxi A., Petta S., Calvaruso V., Brunetto M., Coco B., Chessa L., Pasetto M.C., Bigliotti E., Tamburrini F., Montalto G., Capitano A.R., Ieluzzi D., Fattovich G., Zignego A.L., Monti M., Gragnani L., Zuin M., Finati E., Giorgini A., Angarano G., Milella M., Alessandro F., Dallio M., Mazzella G., Lazzarini G., Di Fine M., Russo F.P., Zanetto A., Castelli F., Zaltron S., Raimondo G., Filomia R., Puoti M., Danieli E., Strazzabosco M., Gemma M., Angelico M., De Leonardis F., Gori A., Cappelletti E., Bruno R., Cima S., Coppola C., Amoruso D.C., Andreone P., Simonetti G., Gaeta G.B., Brancaccio G., Toniutto P., Dissegna D., Mondelli M., Ludovisi S., Persico M., Masarone M., Torti C., Strazzulla A., Rosina F., Framarin L., Weimer L.E., Quaranta M.G., Falzano L., and Mallano A.
- Subjects
Hepatology ,Hepatitis B ,EASL guidelines ,Treatment ,Interferon ,Entecavir ,Tenofovir ,TAF ,HBsAg ,Hepatocellular carcinoma ,HBV DNA ,HBV reactivation ,Mother to child transmission ,EASL guideline - Abstract
It has come to our attention that the PITER framework investigator, Alessandro Federico, was incorrectly listed as F. Alessandro in the original manuscript. Please note that the correct name of this author is Alessandro Federico (2nd University of Naples). The correct list of PITER investigators is in the footnote below.
- Published
- 2018
10. Pharmacotherapy of Painful Diabetic Neuropathy: A Clinical Update.
- Author
-
Fernandez James, Cornelius, Tripathi, Shiva, Karampatou, Kyriaki, Gladston, Divya V., and Pappachan, Joseph M.
- Subjects
DRUG therapy ,DIABETIC neuropathies ,DIABETES ,OPIOIDS ,PUBLIC health - Abstract
The rising prevalence of diabetes mellitus (DM) leads on to an increase in chronic diabetic complications. Diabetic peripheral neuropathies (DPNs) are common chronic complications of diabetes. Distal symmetric polyneuropathy is the most prevalent form. Most patients with DPN will remain pain-free; however, painful DPN (PDPN) occurs in 6-34% of all DM patients and is associated with reduced health-related-quality-of-life and substantial economic burden. Symptomatic treatment of PDPN and diabetic autonomic neuropathy is the key treatment goals. Using certain patient related characteristics, subjects with PDPN can be stratified and assigned targeted therapies to produce better pain outcomes. The aim of this review is to discuss the various pathogenetic mechanisms of DPN with special reference to the mechanisms leading to PDPN and the various pharmacological and non-pharmacological therapies available for its management. Recommended pharmacological therapies include anticonvulsants, antidepressants, opioid analgesics, and topical medications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study
- Author
-
Mariagrazia Del Buono, Paola Loria, Teresa Pollicino, Stefano Colopi, Elena Bertolini, Guido Marzocchi, Stefano Ballestri, Cristian Caporali, Calogero Cammà, Barbara Lei, Aimilia Karampatou, Gianluigi Giannelli, Fabiola Milosa, Erica Villa, Giuseppe Cabibbo, Marco Enea, Elena Turola, Rosina Maria Critelli, Umberto Cillo, Giorgio Enrico Gerunda, Patrizia Pontisso, Nicola De Maria, María L. Martínez-Chantar, Paola Todesca, Luisa Losi, Livia Maccio, Filippo Schepis, Villa E., Critelli R., Lei B., Marzocchi G., Camma C., Giannelli G., Pontisso P., Cabibbo G., Enea M., Colopi S., Caporali C., Pollicino T., Milosa F., Karampatou A., Todesca P., Bertolini E., Maccio L., Martinez-Chantar M.L., Turola E., Dal Buono M., De Maria N., Ballestri S., Schepis F., Loria P., Gerunda G.E., Losi L., and Cillo U.
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Time Factors ,Carcinoma, Hepatocellular ,Time Factor ,Microarray ,Hepatocellular carcinoma ,molecular carcinogenesis ,Gastroenterology ,liver imaging ,HEPATOCELLULAR CARCINOMA ,LIVER IMAGING ,MOLECULAR CARCINOGENESIS ,MOLECULAR ONCOLOGY ,Aged ,Aged, 80 and over ,Disease Progression ,Female ,Humans ,Liver Neoplasms ,Middle Aged ,Neovascularization, Pathologic ,Prospective Studies ,Survival Rate ,Tumor Burden ,Medicine (all) ,03 medical and health sciences ,molecular oncology ,0302 clinical medicine ,Hepatocellular carcinoma, liver imaging, molecular carcinogenesis, molecular oncology ,Internal medicine ,medicine ,Carcinoma ,Doubling time ,Prospective cohort study ,Survival rate ,business.industry ,Proportional hazards model ,medicine.disease ,Prospective Studie ,030104 developmental biology ,Quartile ,Liver Neoplasm ,030220 oncology & carcinogenesis ,business ,Human - Abstract
Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide high-throughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC.Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V-0 and V-1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of survival were assessed by multivariate Cox model.Results Calculated tumour doubling times ranged from 30 to 621 days (mean, 107 +/- 91 days; median, 83 days) and were divided into quartiles: = 111 days (n= 19). Median survival according to doubling time was significantly lower for the first quartile versus the others (11 vs 41 months, 42, and 47 months, respectively) (p< 0.0001). A five-gene transcriptomic hepatic signature including angiopoietin-2 (ANGPT2), delta-like ligand 4 (DLL4), neuropilin (NRP)/tolloid (TLL)-like 2 (NETO2), endothelial cell-specific molecule-1 (ESM1), and nuclear receptor subfamily 4, group A, member 1 (NR4A1) was found to accurately identify rapidly growing HCCs of the first quartile (ROC AUC: 0.961; 95% CI 0.919 to 1.000; p< 0.0001) and to be an independent factor for mortality (HR: 3.987; 95% CI 1.941 to 8.193, p< 0.0001).Conclusions The hepatic five-gene signature was able to predict HCC growth in individual patient and the consequent risk of death. This implies a role of this molecular tool in the future therapeutic management of patients with HCC.
- Published
- 2015
12. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)
- Author
-
Burra, P, Rodríguez-Castro, K, Guarino, M, Morisco, F, Villa, E, Mazzella, G, Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) (Alisi, A, Balsano, C, Bernabucci, V, Berzigotti, A, Brunetto, M, Bugianesi, E, Calvaruso, V, Cariani, E, Coco, B, Colle, I, Critelli, R, De Martin, E, Del Buono, M, Fabregat, I, Faillaci, F, Fattovich, G, Floreani, A, Garcia-Tsao, G, Housset, C, Karampatou, A, Lei, B, Mangia, A, Martinez-Chantar, Ml, Milosa, F, Nasta, P, Ozben, T, Pollicino, T, Ponti, Ml, Pontisso, P, Reeves, H, Rendina, M, Rodríguez-Castro, Ki, Sagnelli, C, Sebastiani, Giulia, Smedile, A, Taliani, G, Vandelli, C, Vanni, E, Vukotic, R, Zignego, Al), Alisi A, Balsano C, Bernabucci V, Berzigotti A, Brunetto M, Bugianesi E, Burra P, Calvaruso V, Cariani E, Coco B, Colle I, Critelli R, De Martin E, Del Buono M, Fabregat I, Faillaci F, Fattovich G, Floreani A, Garcia-Tsao G, Housset C, Karampatou A, Lei B, Mangia A, Martinez-Chantar ML, Milosa F, Morisco F, Nasta P, Ozben T, Pollicino T, Ponti ML, Pontisso P, Reeves H, Rendina M, Rodríguez-Castro KI, Sagnelli C, Sebastiani G, Smedile A, Taliani G, Vandelli C, Vanni E, Villa E, Vukotic R, Zignego AL, Burra P, Rodríguez-Castro K, Guarino M, Morisco F, Villa E, Mazzella G., Alisi, A, Balsano, C, Bernabucci, V, Berzigotti, A, Brunetto, M, Bugianesi, E, Burra, P, Calvaruso, V, Cariani, E, Coco, B, Colle, I, Critelli, R, De Martin, E, Del Buono, M, Fabregat, I, Faillaci, F, Fattovich, G, Floreani, A, Garcia-Tsao, G, Housset, C, Karampatou, A, Lei, B, Mangia, A, Martinez-Chantar, Ml, Milosa, F, Morisco, F, Nasta, P, Ozben, T, Pollicino, T, Ponti, Ml, Pontisso, P, Reeves, H, Rendina, M, Rodríguez-Castro, Ki, Sagnelli, C, Sebastiani, G, Smedile, A, Taliani, G, Vandelli, C, Vanni, E, Vukotic, R, Zignego, Al, Rodríguez-Castro, K, Guarino, M, Villa, E, Mazzella, G., Garcia Tsao, G, Martinez Chantar, Ml, Morisco, Filomena, Rodríguez Castro, Ki, Rodríguez Castro, K, Guarino, Maria, Alisi, Anna, Balsano, Clara, Bernabucci, Veronica, Berzigotti, Annalisa, Brunetto, Maurizia, Bugianesi, Elisabetta, Burra, Patrizia, Calvaruso, Vincenza, Cariani, Elisabetta, Coco, Barbara, Colle, Isabelle, Critelli, Rosina, De Martin, Eleonora, Del Buono, Mariagrazia, Fabregat, Isabel, Faillaci, Francesca, Fattovich, Giovanna, Floreani, Annarosa, Garcia-tsao, Guadalupe, Housset, Chantal, Karampatou, Aimilia, Lei, Barbara, Mangia, Alessandra, Martinez-chantar, Maria Luz, Milosa, Fabiola, Nasta, Paola, Ozben, Tomri, Pollicino, Teresa, Ponti, Maria Laura, Pontisso, Patrizia, Reeves, Helen, Rendina, Maria, Rodrãguez-castro, Kryssia Isabel, Sagnelli, Caterina, Sebastiani, Giada, Smedile, Antonella, Taliani, Gloria, Vandelli, Carmen, Vanni, Ester, Villa, Erica, Vukotic, Ranka, Zignego, Anna Linda, Rodrãguez-castro, Kryssia, and Mazzella, Giuseppe
- Subjects
Risk Assessment ,Fertility ,Immunosuppression ,Liver transplantation ,Pregnancy ,Immunosuppressive Agent ,Medical ,Hepatology ,Gastroenterology ,Humans ,Obstetric Labor Complication ,Societies, Medical ,Postpartum Period ,Pregnancy Outcome ,Contraception ,Female ,Italy ,Obstetric Labor Complications ,Practice Guidelines as Topic ,Pregnancy Complications ,Immunosuppressive Agents ,Liver Transplantation ,Pregnancy Complication ,surgical procedures, operative ,Societies ,Human - Abstract
After the first successful pregnancy in a liver transplant recipient in 1978, much evidence has accumulated on the course, outcomes and management strategies of pregnancy following liver transplantation. Generally, liver transplantation restores sexual function and fertility as early as a few months after transplant. Considering that one third of all liver transplant recipients are women, that approximately one-third of them are of reproductive age (18-49 years), and that 15% of female liver transplant recipients are paediatric patients who have a >70% probability of reaching reproductive age, the issue of pregnancy after liver transplantation is rather relevant, and obstetricians, paediatricians, and transplant hepatologists ever more frequently encounter such patients. Pregnancy outcomes for both the mother and infant in liver transplant recipients are generally good, but there is an increased incidence of preterm delivery, hypertension/preeclampsia, foetal growth restriction, and gestational diabetes, which, by definition, render pregnancy in liver transplant recipients a high-risk one. In contrast, the risk of congenital anomalies and the live birth rate are comparable to those of the general population. Currently there are still no robust guidelines on the management of pregnancies after liver transplantation. The aim of this position paper is to review the available evidence on pregnancy in liver transplant recipients and to provide national Italian recommendations for clinicians caring for these patients. (C) 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
- Published
- 2016
13. AISF position paper on liver transplantation and pregnancy
- Author
-
Anna Alisi, Clara Balsano, Veronica Bernabucci, Annalisa Berzigotti, Maurizia Brunetto, Elisabetta Bugianesi, Patrizia Burra, Vincenza Calvaruso, Elisabetta Cariani, Barbara Coco, Isabelle Colle, Rosina Critelli, Eleonora De Martin, Mariagrazia Del Buono, Isabel Fabregat, Francesca Faillaci, Giovanna Fattovich, Annarosa Floreani, Guadalupe Garcia-Tsao, Chantal Housset, Aimilia Karampatou, Barbara Lei, Alessandra Mangia, Maria Luz Martinez-Chantar, Fabiola Milosa, Filomena Morisco, Paola Nasta, Tomris Ozben, Teresa Pollicino, Maria Laura Ponti, Patrizia Pontisso, Helen Reeves, Maria Rendina, Kryssia Isabel Rodríguez-Castro, Caterina Sagnelli, Giada Sebastiani, Antonella Smedile, Gloria Taliani, Carmen Vandelli, Ester Vanni, Erica Villa, Ranka Vukotic, Anna Linda Zignego, Kryssia Rodríguez-Castro, Maria Guarino, and Giuseppe Mazzella
- Subjects
medicine.medical_specialty ,Pediatrics ,medicine.medical_treatment ,Population ,Liver transplantation ,Organ transplantation ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,education ,Kidney transplantation ,education.field_of_study ,Pregnancy ,030219 obstetrics & reproductive medicine ,Hepatology ,business.industry ,Gastroenterology ,Immunosuppression ,medicine.disease ,Surgery ,Gestational diabetes ,surgical procedures, operative ,030211 gastroenterology & hepatology ,business - Abstract
After the first successful pregnancy in a liver transplant recipient in 1978, much evidence has accumulated on the course, outcomes and management strategies of pregnancy following liver transplantation. Generally, liver transplantation restores sexual function and fertility as early as a few months after transplant. Considering that one third of all liver transplant recipients are women, that approximately one-third of them are of reproductive age (18–49 years), and that 15% of female liver transplant recipients are paediatric patients who have a >70% probability of reaching reproductive age, the issue of pregnancy after liver transplantation is rather relevant, and obstetricians, paediatricians, and transplant hepatologists ever more frequently encounter such patients. Pregnancy outcomes for both the mother and infant in liver transplant recipients are generally good, but there is an increased incidence of preterm delivery, hypertension/preeclampsia, foetal growth restriction, and gestational diabetes, which, by definition, render pregnancy in liver transplant recipients a high-risk one. In contrast, the risk of congenital anomalies and the live birth rate are comparable to those of the general population. Currently there are still no robust guidelines on the management of pregnancies after liver transplantation. The aim of this position paper is to review the available evidence on pregnancy in liver transplant recipients and to provide national Italian recommendations for clinicians caring for these patients.
- Published
- 2016
14. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)
- Author
-
Karampatou, Aimilia, Han, Xue, Kondili, Loreta A., Taliani, Gloria, Ciancio, Alessia, Morisco, Filomena, Critelli, Rosina Maria, Baraldi, Enrica, Bernabucci, Veronica, Troshina, Giulia, Guarino, Maria, Tagliavini, Simonetta, D'Ambrosio, Federica, Bristot, Laura, Turco, Laura, Rosato, Stefano, Vella, Stefano, Trenti, Tommaso, Neri, Isabella, La Marca, Antonio, Manthena, Shivaji, Goldstein, Andrea S., Bruno, Savino, Bao, Yanjun, Gonzalez, Yuri Sanchez, and Villa, Erica
- Subjects
Hepatology - Published
- 2018
15. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41]
- Author
-
Karampatou, Aimilia, primary, Han, Xue, additional, Kondili, Loreta A., additional, Taliani, Gloria, additional, Ciancio, Alessia, additional, Morisco, Filomena, additional, Critelli, Rosina Maria, additional, Baraldi, Enrica, additional, Bernabucci, Veronica, additional, Troshina, Giulia, additional, Guarino, Maria, additional, Tagliavini, Simonetta, additional, D'Ambrosio, Federica, additional, Bristot, Laura, additional, Turco, Laura, additional, Rosato, Stefano, additional, Vella, Stefano, additional, Trenti, Tommaso, additional, Neri, Isabella, additional, La Marca, Antonio, additional, Manthena, Shivaji, additional, Goldstein, Andrea S., additional, Bruno, Savino, additional, Bao, Yanjun, additional, Gonzalez, Yuri Sanchez, additional, and Villa, Erica, additional
- Published
- 2018
- Full Text
- View/download PDF
16. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV
- Author
-
Karampatou, Aimilia, primary, Han, Xue, additional, Kondili, Loreta A., additional, Taliani, Gloria, additional, Ciancio, Alessia, additional, Morisco, Filomena, additional, Critelli, Rosina Maria, additional, Baraldi, Enrica, additional, Bernabucci, Veronica, additional, Troshina, Giulia, additional, Guarino, Maria, additional, Tagliavini, Simonetta, additional, D'Ambrosio, Federica, additional, Bristot, Laura, additional, Turco, Laura, additional, Rosato, Stefano, additional, Vella, Stefano, additional, Trenti, Tommaso, additional, Neri, Isabella, additional, La Marca, Antonio, additional, Manthena, Shivaji, additional, Goldstein, Andrea S., additional, Bruno, Savino, additional, Bao, Yanjun, additional, Gonzalez, Yuri Sanchez, additional, Villa, Erica, additional, Craxì, A., additional, Petta, S., additional, Calvaruso, V., additional, Brunetto, M., additional, Coco, B., additional, Chessa, L., additional, Pasetto, M.C., additional, Bigliotti, E., additional, Tamburrini, F., additional, Montalto, G., additional, Capitano, A.R., additional, Ieluzzi, D., additional, Fattovich, G., additional, Zignego, A.L., additional, Monti, M., additional, Gragnani, L., additional, Zuin, M., additional, Finati, E., additional, Giorgini, A., additional, Angarano, G., additional, Milella, M., additional, Alessandro, F., additional, Dallio, M., additional, Mazzella, G., additional, Lazzarini, G., additional, Di Fine, M., additional, Russo, F.P., additional, Zanetto, A., additional, Castelli, F., additional, Zaltron, S., additional, Raimondo, G., additional, Filomia, R., additional, Puoti, M., additional, Danieli, E., additional, Strazzabosco, M., additional, Gemma, M., additional, Angelico, M., additional, De Leonardis, F., additional, Gori, A., additional, Cappelletti, E., additional, Bruno, R., additional, Cima, S., additional, Coppola, C., additional, Amoruso, D.C., additional, Andreone, P., additional, Simonetti, G., additional, Gaeta, G.B., additional, Brancaccio, G., additional, Toniutto, P., additional, Dissegna, D., additional, Mondelli, M., additional, Ludovisi, S., additional, Persico, M., additional, Masarone, M., additional, Torti, C., additional, Strazzulla, A., additional, Rosina, F., additional, Framarin, L., additional, Weimer, L.E., additional, Quaranta, M.G., additional, Falzano, L., additional, and Mallano, A., additional
- Published
- 2018
- Full Text
- View/download PDF
17. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C
- Author
-
N. De Maria, Maria Rendina, Ranka Vukotic, P Vignoli, Veronica Bernabucci, A. Di Leo, Aimilia Karampatou, Stefano Gitto, Barbara Lei, Marco Enea, Luisa Losi, Alberto Ferrari, Erica Villa, Antonio Francavilla, and C. Cammà
- Subjects
medicine.medical_specialty ,Hepatitis C virus ,Population ,macromolecular substances ,medicine.disease_cause ,Gastroenterology ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,law ,Virology ,Internal medicine ,Medicine ,education ,education.field_of_study ,Hepatology ,business.industry ,Ribavirin ,technology, industry, and agriculture ,virus diseases ,medicine.disease ,digestive system diseases ,Menopause ,Infectious Diseases ,Endocrinology ,chemistry ,Propensity score matching ,Steatosis ,Metabolic syndrome ,business - Abstract
Summary. Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naive patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-IFNα-2a-treated patients and in 51.2% of Peg-IFNα-2b-treated patients (intention-to-treat; P = 0.139). Age, fibrosis stage and genotype 2 and 3 were independently associated with SVR by multivariate analysis. Analysing by gender, the difference in SVR between PEG-IFNα types was not significant in men but highly significant in women (Peg-IFNα-2a:39.1%vs Peg-IFNα-2b:54.4%, P = 0.007). This was attributable to a higher SVR rate with Peg-IFNα-2b in the difficult postmenopausal population (26.9% Peg-IFNα-2a vs 46.0% Peg-IFNα-2b, P = 0.040). In women, absence of menopause, genotype 2 hepatitis C virus infection and use of Peg-IFNα-2b were independently associated with SVR. In conclusion, predictive factors for SVR are different in men and women. Factors differing between genders are menopause, severe steatosis and peg-interferon used. The higher SVR rate with Peg-IFNα-2b in menopausal women is likely attributable to more favourable pharmacokinetics that allows Peg-IFNα-2b to reach visceral fat and oppose the increased cytokine production and enhanced inflammatory status in menopause.
- Published
- 2012
18. Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C
- Author
-
Erica Villa, Aimilia Karampatou, Pietro Andreone, Stefano Gitto, Gitto S, Karampatou A, Andreone P, and Villa E
- Subjects
Oncology ,Microbiology (medical) ,Male ,medicine.medical_specialty ,ANTIVIRAL TREATMENT ,Hepacivirus ,FEMALE SEX ,Alpha interferon ,CHRONIC HEPATITIS C ,Antiviral Agents ,Polyethylene Glycols ,HCV ,Menopause ,chemistry.chemical_compound ,Chronic hepatitis ,Internal medicine ,Ribavirin ,medicine ,Humans ,biology ,business.industry ,Antiviral therapy ,Female sex ,virus diseases ,Interferon-alpha ,General Medicine ,Hepatology ,Hepatitis C, Chronic ,biology.organism_classification ,medicine.disease ,Infectious Diseases ,chemistry ,Immunology ,Female ,business - Published
- 2012
19. Reproductive status is associated with the severity of fibrosis in women with hepatitis C
- Author
-
Roberta Gelmini, Veronica Bernabucci, Enrica Baraldi, Alfredo Di Leo, Simonetta Tagliavini, Elena Turola, Antonio Francavilla, Annamaria Cenci, Luisa Losi, Elena Bertolini, Calogero Cammà, Salvatore Petta, Ranka Vukotic, Stefano Gitto, Aimilia Karampatou, Nicola De Maria, Erica Villa, Maria Rendina, Villa, E, Vukotic, R, Cammà, C, Petta, S, Di Leo, A, Gitto, S, Turola, E, Karampatou, A, Losi, L, Bernabucci, V, Cenci, A, Tagliavini, S, Baraldi, E, De Maria, N, Gelmini, R, Bertolini, E, Rendina, M, and Francavilla, A
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Gastroenterology and hepatology ,Liver Cirrhosi ,Physiology ,lcsh:Medicine ,Viral diseases ,Chronic hepatitis C ,Severity of Illness Index ,Hepatitis ,Liver disease ,Endocrinology ,Fibrosis ,Retrospective Studie ,Severity of illness ,medicine ,gender ,Humans ,Reproductive Endocrinology ,lcsh:Science ,Testosterone ,Liver diseases ,Retrospective Studies ,Gynecology ,Multidisciplinary ,medicine.diagnostic_test ,business.industry ,lcsh:R ,Case-control study ,Hepatitis C ,medicine.disease ,Menopause ,Infectious hepatitis ,Cirrhosis ,Liver biopsy ,Case-Control Studies ,Medicine ,Infectious diseases ,Women's Health ,Female ,lcsh:Q ,business ,Case-Control Studie ,Infertility, Female ,Research Article ,Human - Abstract
Introduction Chronic hepatitis C is the main cause of death in patients with end-stage liver disease. Prognosis depends on the increase of fibrosis, whose progression is twice as rapid in men as in women. Aim of the study was to evaluate the effects of reproductive stage on fibrosis severity in women and to compare these findings with age-matched men. Materials and Methods A retrospective study of 710 consecutive patients with biopsy-proven chronic hepatitis C was conducted, using data from a clinical database of two tertiary Italian care centers. Four age-matched groups of men served as controls. Data about demographics, biochemistry, liver biopsy and ultrasonography were analyzed. Contributing factors were assessed by multivariate logistic regression analysis. Results Liver fibrosis was more advanced in the early menopausal than in the fully reproductive (P
- Published
- 2012
20. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C
- Author
-
Veronica Bernabucci, Antonio Francavilla, Monica Luongo, Salvatore Petta, Anna Ferrari, Alessandro Antonelli, Alfredo Di Leo, Amalia Graziosi, Gloria Taliani, P. Trande, Aimilia Karampatou, Rosina Maria Critelli, Calogero Cammà, Luisa Losi, Barbara Lei, Maria Rendina, Erica Villa, Paola Pazienza, Villa, E, Karampatou, A, Cammà, C, Di Leo, A, Luongo, M, Ferrari, A, Petta, S, Losi, L, Taliani, G, Trande, P, Lei, B, Graziosi, A, Bernabucci, V, Critelli, R, Pazienza, P, Rendina, M, Antonelli, A, and Francavilla, A.
- Subjects
Liver Cirrhosis ,Male ,Time Factors ,medicine.medical_treatment ,Biopsy ,Menopause, Premature ,menopause ,Hepacivirus ,medicine.disease_cause ,Gastroenterology ,Severity of Illness Index ,Risk Factors ,Odds Ratio ,Prospective Studies ,Treatment Failure ,Prospective cohort study ,medicine.diagnostic_test ,Age Factors ,Hormone replacement therapy (menopause) ,Hepatitis C ,Middle Aged ,Viral Load ,Immunohistochemistry ,Menopause ,Italy ,Liver biopsy ,RNA, Viral ,Female ,Inflammation Mediators ,hcv svr menopause ,Viral load ,Adult ,medicine.medical_specialty ,antiviral therapy ,prognostic factors ,hcv therapy ,Genotype ,Hepatitis C virus ,Antiviral Agents ,Risk Assessment ,Sex Factors ,Internal medicine ,hcv ,medicine ,Humans ,ifn ,Hepatology ,business.industry ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,Odds ratio ,Hepatitis C, Chronic ,medicine.disease ,Endocrinology ,Logistic Models ,business ,Biomarkers - Abstract
Background & Aims Chronic hepatitis C (CHC) and liver fibrosis progress more rapidly in men and menopausal women than in women of reproductive age. We investigated the associations among menopause, sustained virologic response (SVR), and liver damage in patients with CHC. Methods We performed a prospective study of 1000 consecutive, treatment-naive patients 18 years of age and older with compensated liver disease from CHC. Liver biopsy samples were analyzed (for fibrosis, inflammation, and steatosis) before patients received standard antiviral therapy. From women (n = 442), we collected data on the presence, type, and timing of menopause; associated hormone and metabolic features; serum levels of interleukin-6; and hepatic tumor necrosis factor (TNF)-α. Results Postmenopausal women achieved SVRs less frequently than women of reproductive age (46.0% vs 67.5%; P P = .283). By multivariate regression analysis, independent significant predictors for women to not achieve an SVR were early menopause (odds ratio [OR], 8.055; 95% confidence interval [CI], 1.834–25.350), levels of γ-glutamyl transpeptidase (OR, 2.165; 95% CI, 1.364–3.436), infection with hepatitis C virus genotype 1 or 4 (OR, 3.861; 95% CI, 2.433–6.134), and cholesterol levels (OR, 0.985; 95% CI, 0.971–0.998). Early menopause was the only independent factor that predicted lack of an SVR among women with genotype 1 hepatitis C virus infection (OR, 3.933; 95% CI, 1.274–12.142). Baseline levels of liver inflammation, fibrosis, steatosis, serum interleukin-6 ( P = .04), and hepatic TNF-α ( P = .007) were significantly higher among postmenopausal women than women of reproductive age. Conclusions Among women with CHC, early menopause was associated with a low likelihood of SVR, probably because of inflammatory factors that change at menopause.
- Published
- 2010
21. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study
- Author
-
Villa, Erica, primary, Critelli, Rosina, additional, Lei, Barbara, additional, Marzocchi, Guido, additional, Cammà, Calogero, additional, Giannelli, Gianluigi, additional, Pontisso, Patrizia, additional, Cabibbo, Giuseppe, additional, Enea, Marco, additional, Colopi, Stefano, additional, Caporali, Cristian, additional, Pollicino, Teresa, additional, Milosa, Fabiola, additional, Karampatou, Aimilia, additional, Todesca, Paola, additional, Bertolini, Elena, additional, Maccio, Livia, additional, Martinez-Chantar, Maria Luz, additional, Turola, Elena, additional, Del Buono, Mariagrazia, additional, De Maria, Nicola, additional, Ballestri, Stefano, additional, Schepis, Filippo, additional, Loria, Paola, additional, Enrico Gerunda, Giorgio, additional, Losi, Luisa, additional, and Cillo, Umberto, additional
- Published
- 2015
- Full Text
- View/download PDF
22. Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis
- Author
-
Cristian Caporali, Cristina Tata, Monica Luongo, Ramona Zecchini, Aimilia Karampatou, Elena Turola, Barbara Lei, Stefano Gitto, Mariagrazia Del Buono, Beatrice Zambotto, Salvatore Petta, Ranka Vukotic, Marco Marietta, Anna Ferrari, Rosina Maria Critelli, Giovanni Fornaciari, Filippo Schepis, Stefano Colopi, Veronica Bernabucci, Calogero Cammà, Dominique Valla, Luisa Simoni, Erica Villa, Nicola De Maria, Susanna Schianchi, Villa, E, Camma', C, Marietta, M, Luongo, M, Critelli, R, Colopi, S, Tata, C, Zecchini, R, Gitto, S, Petta, S, Lei, B, Bernabucci, V, Vukotic, R, De Maria, N, Schepis, F, Karampatou, A, Caporali, C, Simoni, L, Del Buono, M, Zambotto, B, Turola, E, Fornaciari, G, Schianchi, S, Ferrari, A, and Valla, D
- Subjects
medicine.medical_specialty ,Cirrhosis ,Intention-to-treat analysis ,Hepatology ,business.industry ,cirrhosis ,Gastroenterology ,Portal vein trombosis ,Enoxaparin ,enoxaparin, cirrhosis, portal thrombosis ,medicine.disease ,Surgery ,Portal vein thrombosis ,law.invention ,Spontaneous bacterial peritonitis ,Model for End-Stage Liver Disease ,Randomized controlled trial ,law ,Hepatocellular carcinoma ,Medicine ,Portal hypertension ,business - Abstract
BACKGROUND & AIMS: We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS: In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was prevention of PVT. Radiologists and hepatologists that assessed outcomes were blinded to group assignments. Analysis was by intention to treat. RESULTS: At 48 weeks, none of the patients in the enoxaparin group had developed PVT, compared with 6 of 36 (16.6%) controls (P = .025). At 96 weeks, no patient developed PVT in the enoxaparin group, compared with 10 of 36 (27.7%) controls (P = .001). At the end of the follow-up period, 8.8% of patients in the enoxaparin group and 27.7% of controls developed PVT (P = .048). The actuarial probability of PVT was lower in the enoxaparin group (P = .006). Liver decompensation was less frequent among patients given enoxaparin (11.7%) than controls (59.4%) (P < .0001); overall values were 38.2% vs 83.0%, respectively (P < .0001). The actuarial probability of liver decompensation was lower in the enoxaparin group (P < .0001). Eight patients in the enoxaparin group and 13 controls died. The actuarial probability of survival was higher in the enoxaparin group (P = .020). No relevant side effects or hemorrhagic events were reported. CONCLUSIONS: In a small randomized controlled trial, a 12-month course of enoxaparin was safe and effective in preventing PVT in patients with cirrhosis and a Child-Pugh score of 7-10. Enoxaparin appeared to delay the occurrence of hepatic decompensation and to improve survival.
- Published
- 2012
23. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study.
- Author
-
Villa, Erica, Critelli, Rosina, Lei, Barbara, Marzocchi, Guido, Cammà, Calogero, Giannelli, Gianluigi, Pontisso, Patrizia, Cabibbo, Giuseppe, Enea, Marco, Colopi, Stefano, Caporali, Cristian, Pollicino, Teresa, Milosa, Fabiola, Karampatou, Aimilia, Todesca, Paola, Bertolini, Elena, Maccio, Livia, Martinez-Chantar, Maria Luz, Turola, Elena, and Buono, Mariagrazia Del
- Subjects
LIVER cancer ,LIVER tumors ,CIRRHOSIS of the liver ,HETEROGENEITY ,TREATMENT of cirrhosis of the liver ,DIAGNOSIS - Abstract
Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide highthroughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC. Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V0 and V1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of survival were assessed by multivariate Cox model. Results Calculated tumour doubling times ranged from 30 to 621 days (mean, 107±91 days; median, 83 days) and were divided into quartiles: ⩽53 days (n=19), 54-82 days (n=20), 83-110 days (n=20) and ⩾111 days (n=19). Median survival according to doubling time was significantly lower for the first quartile versus the others (11 vs 41 months, 42, and 47 months, respectively) (p<0.0001). A five-gene transcriptomic hepatic signature including angiopoietin-2 (ANGPT2), delta-like ligand 4 (DLL4), neuropilin (NRP)/tolloid (TLL)-like 2 (NETO2), endothelial cell-specific molecule-1 (ESM1), and nuclear receptor subfamily 4, group A, member 1 (NR4A1) was found to accurately identify rapidly growing HCCs of the first quartile (ROC AUC: 0.961; 95% CI 0.919 to 1.000; p<0.0001) and to be an independent factor for mortality (HR: 3.987; 95% CI 1.941 to 8.193, p<0.0001). Conclusions The hepatic five-gene signature was able to predict HCC growth in individual patient and the consequent risk of death. This implies a role of this molecular tool in the future therapeutic management of patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Reproductive Status Is Associated with the Severity of Fibrosis in Women with Hepatitis C
- Author
-
Villa, Erica, primary, Vukotic, Ranka, additional, Cammà, Calogero, additional, Petta, Salvatore, additional, Di Leo, Alfredo, additional, Gitto, Stefano, additional, Turola, Elena, additional, Karampatou, Aimilia, additional, Losi, Luisa, additional, Bernabucci, Veronica, additional, Cenci, Annamaria, additional, Tagliavini, Simonetta, additional, Baraldi, Enrica, additional, De Maria, Nicola, additional, Gelmini, Roberta, additional, Bertolini, Elena, additional, Rendina, Maria, additional, and Francavilla, Antonio, additional
- Published
- 2012
- Full Text
- View/download PDF
25. Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C
- Author
-
Gitto, Stefano, primary, Karampatou, Aimilia, additional, Andreone, Pietro, additional, and Villa, Erica, additional
- Published
- 2012
- Full Text
- View/download PDF
26. Early Menopause Is Associated With Lack of Response to Antiviral Therapy in Women With Chronic Hepatitis C
- Author
-
Villa, Erica, primary, Karampatou, Aimilia, additional, Cammà, Calogero, additional, Di Leo, Alfredo, additional, Luongo, Monica, additional, Ferrari, Anna, additional, Petta, Salvatore, additional, Losi, Luisa, additional, Taliani, Gloria, additional, and Trande, Paolo, additional
- Published
- 2011
- Full Text
- View/download PDF
27. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV.
- Author
-
Karampatou A, Han X, Kondili LA, Taliani G, Ciancio A, Morisco F, Critelli RM, Baraldi E, Bernabucci V, Troshina G, Guarino M, Tagliavini S, D'Ambrosio F, Bristot L, Turco L, Rosato S, Vella S, Trenti T, Neri I, La Marca A, Manthena S, Goldstein AS, Bruno S, Bao Y, Gonzalez YS, and Villa E
- Abstract
Background & Aims: Premenopausal women who are HCV positive (HCV+) have failing ovarian function, which is likely to impact their fertility. Thus, we investigated the reproductive history, risk of infertility, and pregnancy outcomes in women of childbearing age who were HCV+., Methods: Three different groups were studied: (1) Clinical cohort: 100 women who were HCV+ and also had chronic liver disease (CLD), age matched with 50 women who were HBV+ with CLD and with 100 healthy women; all women were consecutively observed in three gastroenterology units in hospitals in Italy; (2) 1,998 women who were HCV+ and enrolled in the Italian Platform for the Study of Viral Hepatitis Therapies (PITER); (3) 6,085 women, who were mono-infected with HCV, and 20,415 women, who were HCV-, from a large de-identified insurance database from the USA., Measurements: total fertility rate (TFR) defined as the average number of children that a woman would bear during her lifetime. To define the reproductive stage of each participant, levels of anti-Müllerian hormone (AMH) and 17β-estradiol were measured., Results: Clinical cohort: women who were either HCV+ or HBV+ had similar CLD severity and age at first pregnancy. Based on a multivariate analysis, women who were HCV+ had a higher risk of miscarriage than those who were HBV+ (odds ratio [OR] 6,905; 95% CI 1.771-26.926). Among women who were HCV+, incidence of miscarriage was correlated with median AMH level (1.0 ng/ml). Achieving a sustained virologic response (SVR) after antiviral treatment reduced the risk of miscarriage (OR 0.255; 95% CI 0.090-0.723). In the PITER-HCV cohort, miscarriage occurred in 42.0% of women (44.6% had multiple miscarriages). TFR for women who were HCV+ and between 15 and 49 years of age was 0.7 vs. 1.37 of Italian population of the same age range. In the US cohort: compared with women who were HCV-, women who were HCV+ positive were significantly more likely to have infertility (OR 2.439; 95% CI 2.130-2.794), premature birth (OR 1.34; 95% CI 1.060-1.690), gestational diabetes (OR 1.24; 95% CI 1.020-1.510), and pre-eclampsia (OR 1.206; 95% CI 0.935-1.556), and were less likely to have a live birth (OR 0.754; 95% CI 0.622-0.913)., Conclusions: Ovarian senescence in women of childbearing age who are HCV+ is associated with a lower chance of live birth, greater risk of infertility, gestational diabetes, pre-eclampsia and miscarriage. Such risks could be positively influenced by successful HCV cure., Lay Summary: Most new cases of HCV infection are among people who inject drugs, many of whom are young women in their childbearing years. Women of reproductive age who are HCV+ display markers of ovarian senescence. This is associated with an increased burden in terms of infertility and adverse pregnancy outcomes, including stillbirth, miscarriage, fewer live births, and gestational diabetes. Early viral suppression with therapy is likely to mitigate these risks., (Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
28. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
- Author
-
Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, and Villa E
- Subjects
- Antiviral Agents adverse effects, Biomarkers blood, Drug Therapy, Combination, Female, Genotype, Hepacivirus genetics, Hepacivirus pathogenicity, Hepatitis C, Chronic blood, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Interferon-alpha therapeutic use, Italy, Logistic Models, Middle Aged, Multivariate Analysis, Odds Ratio, Polyethylene Glycols therapeutic use, Proline adverse effects, Proline therapeutic use, RNA, Viral blood, Recombinant Proteins therapeutic use, Ribavirin therapeutic use, Time Factors, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Hepacivirus drug effects, Hepatitis C, Chronic drug therapy, Menopause, Proline analogs & derivatives
- Abstract
Aim: To investigate the safety/efficacy of Boceprevir-based triple therapy in hepatitis C virus (HCV)-G1 menopausal women who were historic relapsers, partial-responders and null-responders., Methods: In this single-assignment, unblinded study, we treated fifty-six menopausal women with HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure (7% null, 41% non-responder, and 52% relapser) with 4 wk lead-in with PEG-IFNα2b/RBV followed by PEG-IFNα2b/RBV+Boceprevir for 32 wk, with an additional 12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNA-positive by week 8. In previous null-responders, 44 wk of triple therapy was used. The primary objective of retreatment was to verify whether a sustained virological response (SVR) (HCV RNA undetectable at 24 wk of follow-up) rate of at least 20% could be obtained. The secondary objective was the evaluation of the percent of patients with negative HCV RNA at week 4 (RVR), 8 (RVR BOC), 12 (EVR), or at the end-of-treatment (ETR) that reached SVR. To assess the relationship between SVR and clinical and biochemical parameters, multiple logistic regression analysis was used., Results: After lead-in, only two patients had RVR; HCV-RNA was unchanged in all but 62% who had ≤ 1 log10 decrease. After Boceprevir, HCV RNA became undetectable at week 8 in 32/56 (57.1%) and at week 12 in 41/56 (73.2%). Of these, 53.8% and 52.0%, respectively, achieved SVR. Overall, SVR was obtained in 25/56 (44.6%). SVR was achieved in 55% previous relapsers vs. 41% non-responders (P = 0.250), in 44% F0-F2 vs 54% F3-F4 (P = 0.488), and in 11/19 (57.9%) of patients with cirrhosis. At univariate analysis for baseline predictors of SVR, only previous response to antiviral therapy (OR = 2.662, 95%CI: 0.957-6.881, P = 0.043), was related with SVR. When considering "on treatment" factors, 1 log10 HCV RNA decline at week 4 (3.733, 95%CI: 1.676-12.658, P = 0.034) and achievement of RVR BOC (7.347, 95%CI: 2.156-25.035, P = 0.001) were significantly related with the SVR, although RVR BOC only (6.794, 95%CI: 1.596-21.644, P = 0.010) maintained significance at multivariate logistic regression analysis. Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplementation, respectively. Only six patients discontinued therapy., Conclusion: Boceprevir obtained high SVR response independent of previous response, RVR or baseline fibrosis or cirrhosis. RVR BOC was the only independent predictor of SVR.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.